Pepdexpepdex
Stack
← Back to peptides
Comparison

Amycretin vs Retatrutide

Amycretin vs Retatrutide: Novo's GLP-1 + amylin co-agonist vs Lilly's GLP-1 + GIP + glucagon triple agonist. The two most-watched next-generation obesity compounds, both pre-approval.

The verdict

Two of the most-watched next-generation obesity compounds, and neither is approved yet. Amycretin is Novo's single-molecule GLP-1 plus amylin co-agonist, notable for having both an injectable and an oral form and for some of the highest early weight-loss numbers in the class. Retatrutide is Lilly's triple agonist (GLP-1, GIP, glucagon), which has posted the largest trial weight-loss figures in the class. Retatrutide is already in Phase 3; Amycretin is now advancing to it. If the headline is raw effect size, Retatrutide leads on the numbers so far; Amycretin's real draw is the oral option in a field that is almost entirely injectable. For now both are investigational, so source quality is the actual risk, not the mechanism.

№ 066
Amycretin
Fat LossEvidence: Moderate

Amycretin is Novo Nordisk's experiment in putting Semaglutide and Cagrilintide together as one molecule instead of two separate drugs. Activates GLP-1 + amylin in a single injection. They're testing both an oral pill and a weekly injection. Phase 1/2 only, not available yet.

Onset
80
Documentation
95
Side intensity
64
Popularity
55
№ 003
Retatrutide
Fat LossEvidence: Moderate

Retatrutide is the newest weight-loss compound in development at Eli Lilly. It's a stronger cousin of Tirzepatide (Mounjaro / Zepbound) and pulls bigger weight loss in trials, often 20%+ of body weight. One injection per week. Side effects are real, especially in the first few weeks.

Onset
80
Documentation
95
Side intensity
100
Popularity
90
Side-by-side
Field
Left
Right
Category
Fat Loss
Fat Loss
Half-life
~5-7 days (sub-q form)
~6 days
Route
Subcutaneous (sub-q form) or oral (oral form)
Subcutaneous
Schedule
Once weekly (sub-q) or once daily (oral)
Once weekly
Cycle length
Trial protocols
Open-ended, titrate over 4-6 months
Dose
Trial doses still being established. Sub-q forms tested up to 60 mg weekly (Lancet phase 1b/2a, ~24% weight loss at 36 weeks).
Start 2mg sub-q weekly. Titrate by 2mg every 4 weeks based on tolerance. Trials went up to 12mg; most users plateau benefit at 8-12mg.
FDA
Investigational. Phase 1/2 trials by Novo Nordisk in oral and subcutaneous formulations.
Investigational. In Phase 3 trials with Eli Lilly. Not yet approved.
WADA
Not listed
Not listed
Natty?
Not natty
Not natty
Prescribed
Trial access only.
Not yet available by prescription. Trial-only access through Lilly's clinical program.
Top side effects
Nausea (less than Semaglutide monotherapy in early data); Reduced appetite; Constipation
Nausea (especially first 2 weeks of each titration step); Vomiting; Constipation or diarrhea

Which one should you pick?

Pick Amycretin if trial participants in obesity studies or followers of novo's next-generation pipeline.

Pick Retatrutide if people plateaued on tirzepatide or users targeting >15% body weight loss.

AI Coach · free

Still torn between Amycretin and Retatrutide?

The AI Coach reads both, asks about your goal and experience, and tells you which one actually fits — plus how to dose and stack it. Free.

Ask the Coach: Amycretin vs Retatrutide →
Full entry
№ 066 Amycretin →
Full entry
№ 003 Retatrutide →
Free, no account needed

Want the latest evidence updates?

Drop your email and we'll send you the one-page checklist for vetting any peptide before you trust a vendor or a forum: what to verify, the red flags, and the questions to ask a licensed provider. No card.

No spam, and we never sell your email. Just the checklist. Email support@pepdex.co to opt out any time.